Impact of diabetes mellitus on lymphocyte GRK2 protein levels in patients with heart failure

European Journal of Clinical Investigation

Volumn 45, Issue 2, 2015, Pages 187-195

  Rengo, Giuseppe ^a   Pagano, Gennaro ^b,c   Paolillo, Stefania ^c   de Lucia, Claudio ^c   Femminella, Grazia D ^c   Liccardo, Daniela ^c   Cannavo, Alessandro ^c   Formisano, Roberto ^c   Petraglia, Laura ^c   Komici, Klara ^c   Rengo, Franco ^a   Trimarco, Bruno ^c   Ferrara, Nicola ^a,c   Leosco, Dario ^c   Perrone Filardi, Pasquale ^c  

^a IRCCS   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Beta adrenergic receptor; Diabetes; Functional recovery; GRK2; Heart failure; Sympathetic nervous system

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; G PROTEIN COUPLED RECEPTOR KINASE 2; INSULIN; NORADRENALIN; ORAL ANTIDIABETIC AGENT; ADRBK1 PROTEIN, HUMAN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC DIET; DIET; ENZYME BLOOD LEVEL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INSULIN TREATMENT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; CLINICAL TRIAL; DIABETIC ANGIOPATHY; METABOLISM; MULTICENTER STUDY;

AGED; DIABETIC ANGIOPATHIES; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART FAILURE; HUMANS; LYMPHOCYTES; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84921450860     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12395     Document Type: Article

References (36)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
2. Rengo F, Leosco D, Iacovoni A, Rengo G, Golino L, Borgia F et al. Epidemiology and risks factor for heart failure in the elderly. Ital Heart J 2004;5:3S-10S.
3. Soläng L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999;20:789-95.
4. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
5. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20.
6. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 2013;113:739-53.
7. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-62.
8. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009;54:375-85.
9. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
10. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
11. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2011;57:356-65.
12. Rengo G, Lymperopoulos A, Koch WJ. Future G protein-coupled receptor targets for treatment of heart failure. Curr Treat Options Cardiovasc Med 2009;11:328-38.
13. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE et al. Myocardial AAV6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009;119:89-98.
14. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 2005;26:1752-8.
15. Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C et al. Targeting the β-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail 2012;5:385-91.
16. Bonita RE, Raake PW, Otis NJ, Chuprun JK, Spivack T, Dasgupta A et al. Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci 2010;3:14-8.
17. Rengo G, Galasso G, Femminella GD, Parisi V, Zincarelli C, Pagano G et al. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur J Prev Cardiol 2014;21:4-11.
18. Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Femminella GD et al. Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care 2013;36:2395-401.
19. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-13.
20. Ciccarelli M, Chuprun JK, Rengo G, Gao E, Wei Z, Peroutka RJ et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 2011;123:1953-62.
21. von EE, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
22. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
23. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 2001;23:45-55.
24. Thackeray JT, Beanlands RS, DaSilva JN. Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging. Am J Nucl Med Mol Imaging 2012;2:314-34.
25. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005;54:3592-601.
26. Porojan M, Costin S, Poantă L, Cerghizan A, Pop D, Dumitraşcu DL. Autonomic neuropathy and plasma catecholamine in patients with diabetes mellitus. Rom J Intern Med 2010;48:341-5.
27. Zhang L, Xiong XQ, Fan ZD, Gan XB, Gao XY, Zhu GQ. Involvement of enhanced cardiac sympathetic afferent reflex in sympathetic activation in early stage of diabetes. J Appl Physiol (1985) 2012;113:47-55.
28. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW, Smythe GA. The effects of sympathetic nervous system activation and psychological stress on glucose metabolism and blood pressure in subjects with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:835-43.
29. Uriel N, Gonzalez-Costello J, Mignatti A, Morrison KA, Nahumi N, Colombo PC et al. Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. JACC Heart Fail 2013;1:331-7.
30. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al. ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
31. Yufu K, Takahashi N, Okada N, Shinohara T, Nakagawa M, Hara M et al. Cardiac iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 diabetic patients without structural heart disease. Circ J 2012;76:399-404.
32. Gerson MC, Caldwell JH, Ananthasubramaniam K, Clements IP, Henzlova MJ, Amanullah A et al. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging 2011;4:87-93.
33. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, Gargiulo P, Savarese G, Marciano C et al. Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Heart 2011;97:1828-33.
34. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Condorelli G et al. Akt mediates the cross-talk between betaadrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 2005;96:180-8.
35. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012;125:2844-53.
36. Hata JA, Williams ML, Schroder JN, Lima B, Keys JR, Blaxall BC et al. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta adrenergic signaling after mechanical unloading. J Card Fail 2006;12:360-8.